Definium's LSD Pill Wins Phase 3 in Anxiety — What It Means for Psychiatry

DT120 beat placebo by 5.4 points on the Hamilton Anxiety scale twelve weeks after a single dose — the first new mechanism in generalized anxiety disorder since 2007, and the real constraint isn't efficacy, it's who pays for the eight-hour monitored session. We break down Definium Therapeutics' Voyage results and the September Panorama readout that decides the functional-unblinding question. Plus: Eli Lilly files six lawsuits over a retatrutide black market before the obesity drug is even submitted for approval, Alfasigma acquires Nordic Group to expand its rheumatology portfolio and reach into Japan and Canada, Freenome wins FDA Breakthrough Device Designation for a blood-based lung cancer screening test, and Boulevard Bio launches with $65 million for bispecific antibodies in IgA nephropathy. Visit us at thepharmacloseout.com.